Key insights
- Grail Inc.'s Chief Growth Officer sold $91,070 in common stock via a 'sell-to-cover' transaction to cover withholding taxes. This occurred amidst a recent 16% stock decline, though the stock is up 56% year-over-year. The company reported Q1 earnings with revenue slightly beating expectations, but EPS was negative. Analyst ratings from Goldman Sachs and Wolfe Research were initiated at Neutral and Peerperform, respectively, citing regulatory and
Andrew John Partridge, Chief Growth Officer at GRAIL, Inc. (NASDAQ:GRAL), disposed of 1,491 shares of the company’s common stock on June 4, 2026. The transaction was valued at $91,070, with shares sold at a weighted average price of $61.08 each.The sale comes as GRAIL’s stock has declined sharply, with shares currently trading at $59.98 after dropping 16% over the past week. Despite this recent weakness, the stock has delivered a 56% return over the past year, according to InvestingPro data, which tracks comprehensive metrics for over 1,400 US equities.
According to a recent SEC Form 4 filing, the sale represented an automatic "sell-to-cover" transaction. This mechanism is typically used by an executing broker to cover withholding taxes associated with award vesting and the subsequent delivery of shares. The shares were sold as part of a block trade, and the reported price reflects a weighted average across multiple transactions. Following this disposition, Mr. Partridge directly holds 163,738 shares of GRAIL, Inc. common stock.
In other recent news, Grail Inc. reported its first-quarter 2026 earnings, with revenue reaching 40.8 million USD, exceeding analyst predictions of 40.4 million USD. Despite a negative earnings per share of -2.29 USD, the company’s revenue growth was noted. Grail also announced mixed results from its PATHFINDER 2 study, which assessed the Galleri multi-cancer early detection test. The study involved 35,878 participants and demonstrated a 6.5-fold increase in cancer detection when combined with standard screenings for several cancers.
In terms of analyst coverage, Goldman Sachs initiated coverage on Grail with a Neutral rating, citing regulatory approval and reimbursement uncertainties as significant factors. Wolfe Research also started coverage with a Peerperform rating, highlighting the company’s valuation compared to its diagnostics peers. These developments reflect ongoing interest and evaluation from the investment community regarding Grail’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for GRAL plus thousands of other stocks and find your next hidden gem with massive upside.